Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to $18.1 million.

  • Amicus Therapeutics' Share-based Compensation fell 3.21% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.0 million, marking a year-over-year decrease of 4.47%. This contributed to the annual value of $84.9 million for FY2024, which is 1.36% down from last year.
  • Per Amicus Therapeutics' latest filing, its Share-based Compensation stood at $18.1 million for Q3 2025, which was up 3.02% from $17.6 million recorded in Q2 2025.
  • Amicus Therapeutics' Share-based Compensation's 5-year high stood at $34.9 million during Q1 2023, with a 5-year trough of $11.7 million in Q2 2021.
  • Its 3-year average for Share-based Compensation is $21.1 million, with a median of $18.1 million in 2023.
  • Examining YoY changes over the last 5 years, Amicus Therapeutics' Share-based Compensation showed a top increase of 61.59% in 2021 and a maximum decrease of 25.57% in 2021.
  • Over the past 5 years, Amicus Therapeutics' Share-based Compensation (Quarterly) stood at $13.9 million in 2021, then skyrocketed by 33.93% to $18.6 million in 2022, then declined by 2.85% to $18.1 million in 2023, then increased by 6.20% to $19.2 million in 2024, then fell by 3.21% to $18.1 million in 2025.
  • Its last three reported values are $18.1 million in Q3 2025, $17.6 million for Q2 2025, and $25.2 million during Q1 2025.